UNITED STATES SECURITIES AND EXCHANGE COMMISSION ~~Washington, D.C. 20549~~

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 orOR 15(d) of ~~the~~The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~August 26, 2010

ReSearch Pharmaceutical Services, Inc. ~~(Exact name of registrant as specified in its charter)~~

Delaware		000-52981		20-4322769
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

(Exact name of registrant as specified in its charter)

520 Virginia Drive, Fort Washington, PA	19034
Delaware	000-52981	20-4322769
(Address of Principal Executive Offices)	(Zip Code)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


520 Virginia Drive, Fort Washington, PA		19034

(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (215) 540-0700

N/A ~~(Former name or former address if changed since last report.)~~

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1Item 2.02 Results of Operations and Financial Condition.

~~Item~~On ~~5.07~~August 6, ~~Submission~~2010, ofReSearch ~~Matters~~Pharmaceutical toServices, Inc. issued a ~~Vote~~press release reporting its financial results for the three and six months ended June 30, 2010. A copy of ~~Security~~the ~~Holders~~press release is attached as an exhibit to this report.

WeThe ~~held~~information ~~our~~furnished ~~2010~~under ~~Annual~~this ~~Meeting~~“Item 2.02. Results of ~~Stockholders~~Operations onand ~~June~~Financial Condition” and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 2,18 ~~2010~~of atthe Securities ~~our~~Exchange ~~corporate~~Act ~~headquarters~~of at1934 ~~520~~(the ~~Virginia~~“Exchange ~~Drive~~Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities ~~Fort~~Act ~~Washington~~of 1933 or the Exchange Act, ~~Pennsylvania~~except ~~19034.~~as ~~The~~shall ~~following~~be ~~proposals~~expressly ~~were~~set ~~submitted~~forth toby ~~our~~specific ~~stockholders:~~reference in such a filing.

•Item 9.01 ~~Proposal~~Financial 1:Statements ~~the election of three Class III directors to serve for a term ending at the Annual Meeting of Stockholders to be held in 2013, or until each of their successors is duly elected~~ and ~~qualified; and~~Exhibits.

~~• Proposal 2: ratification of the appointment by our Audit Committee of Ernst & Young, LLP as our independent auditor for 2010.~~(d) Exhibits

~~Holders of our common stock were entitled to one vote per share on all matters submitted to a vote of stockholders~~99.1 ~~The~~Press ~~Board~~Release ofdated ~~Directors~~August ~~nominated~~6, ~~and the holders of our common stock voted for, the following Class III directors as follows:~~ 2010.

Name	Votes For		Votes Against		Votes Withheld		Broker Non-Votes
Daniel M. Perlman		28,218,015		0		0		0
Harris Koffer		28,218,015		0		0		0
Peter M. Yu		28,218,015		0		0		0

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

The following directors continued as directors after the 2010 Annual Meeting of Stockholders and will be voted on by the stockholders at the 2011 Annual Meeting of Stockholders (Class I) and the 2012 Annual Meeting of Stockholders (Class II).


Date: August 6, 2010	ReSearch Pharmaceutical Services, Inc.
	By:	/s/ Steven Bell
		Steven Bell
		Executive Vice President of Finance Chief Financial Officer

Thomas R. Armstrong Class I James R. Macdonald Class I Stephen E. Stonefield Class I Jack H. Dean Class II Warren W. Myers Class II Daniel Raynor Class II

The results of voting on the remaining proposal were as follows:

		Votes For				Votes Against				Abstentions				Broker Non-Votes
Proposal 2: Ratification of the appointment of Ernst & Young, LLP			28,218,015				0				0				0

All proposals put to the stockholders were approved.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 2, 2010

ReSearch Pharmaceutical Services, Inc.

By: /s/ Steven Bell Steven Bell Executive Vice President of Finance Chief Financial Officer, Secretary and Treasurer

Filing Compare · RESEARCH PHARMACEUTICAL SERVICES, INC.